

FIG.1

2/23




FIG.2




FIG.3




FIG.4





FIG.5

RELATIVE L-ASPARAGINE
UPTAKE INTO CELL MONOLAYER
FROM VEHICLE vs NON-VEHICLE



RELATIVE ACYCLOVIR UPTAKE
INTO CELL MONOLAYER FROM
VEHICLE vs NON-VEHICLE

FIG.6





FIG.7



FORMULATION

FIG.8

□ NO VEHICLE
▨ WITH VEHICLE




FIG.9





FIG.10



□ NO VEHICLE
▨ WITH VEHICLE

FORMULATION

FIG.11




FIG.12

TITLE: IMPROVED TREATMENT OF CANCER WITH GLUTAMINE

INVENTORS NAME: Suzanne V. Klimberg et al.

Dkt #: 781.020US1

13/23




FIG.13




FIG.14

TITLE: IMPROVED TREATMENT OF CANCER WITH GLUTAMINE

INVENTORS NAME: Suzanne V. Klimberg et al.

Dkt #: 781.020US1

14/23




FIG. 15A





FIG. 15B

TITLE: IMPROVED TREATMENT OF CANCER WITH GLUTAMINE

INVENTORS NAME: Suzanne V. Klimberg et al.


Dkt #: 781.020US1

15/23



* $p < 0.05$, ANOVA, OIL+GLN vs. OIL+FA OR OIL+H2O

FIG. 16



* $p < 0.05$, ANOVA, DMBA+GLN vs. DMBA+FA OR DMBA+H2O

FIG. 17

TITLE: IMPROVED TREATMENT OF CANCER WITH GLUTAMINE

INVENTORS NAME: Suzanne V. Klimberg et al.

Dkt #: 781.020US1

16/23




FIG. 18A




FIG. 18B




FIG. 19




FIG. 20




FIG. 21




FIG. 22

TITLE: IMPROVED TREATMENT OF CANCER WITH GLUTAMINE

INVENTORS NAME: Suzanne V. Klimberg et al.

Dkt #: 781.020US1

19/23




FIG. 23




FIG. 24




FIG. 25




FIG. 28




FIG. 27




FIG. 26

TITLE: IMPROVED TREATMENT OF CANCER WITH GLUTAMINE

INVENTORS NAME: Suzanne V. Klimberg et al.

Dkt #: 781.020US1

22/23




FIG. 29





FIG. 30



*p<0.05, ANOVA, DMBA+GLN vs. DMBA+FA OR DMBA+H2O AT WEEK 11, DMBA+GLN vs. OIL+GLN AT WEEK 1

**p<0.05, ANOVA, DMBA+FA vs. OIL+FA AT WEEK 1 & 11

***p<0.05, ANOVA, DMBA+H2O vs. OIL+H2O AT WEEK 1 & 11

FIG. 31